Page 10 - Sanket Koul

M3M to invest ₹2,100 cr in Jacob & Co's branded housing debut in India

M3M Group partners with luxury watchmaker Jacob & Co to build India's first branded residences in Noida, with an investment of Rs 2,100 crore and prices up to Rs 25 crore

India's housing market gets 'premium', with surging value despite sales dip

Housing sales data shows regional imbalance with Southern markets gaining, even as North and West sees dip

WHO issues alert against 3 cough syrups linked to MP children's deaths

CDSCO had earlier informed the global health body that none of the syrups were exported to other countries

Death in a bottle: Toxic cough syrups once again prove fatal for children

Toxic cough syrups have once again proven fatal for children. This time, the tragedy has happened in India. Here's a look at why this sordid tale never seems to let up

Govt to broaden qualification criteria to recruit medical device inspectors

The ministry has issued a draft notification proposing an amendment to add qualifications for inspectors and government analysts under Rule 18 of the Medical Device Rules (MDR), 2017

Drug regulator begins pan-Indian inspection of cough syrup makers

No state has fully complied with Corrective and Preventive Action (CAPA) guidelines, introduced for ensuring safety and maintaining standards in pharma products

Delhi HC dismisses Roche's plea, allows Natco to sell generic Risdiplam

A division bench comprising Justices C Hari Shankar and Ajay Digpaul upheld a March 2025 single-judge bench order that had denied Roche an injunction

Coventry University in talks with Edu Ministry for more India campuses

The UK-based university, which got approval for its first Indian campus in Gujarat's Gift City, plans further expansion under India's National Education Policy 2020

Punjab bans Coldrif, even as PIL in SC seeks probe on cough syrup deaths

With this, the state joins Maharashtra, Kerala and Tamil Nadu, who have already announced bans on the cough syrup

Eli Lilly's Mounjaro logs ₹80 crore in September, India's No. 2 drug

The highest-selling drug for the month was GlaxoSmithKline's Augmentin, an antibiotic, garnering revenues of ₹85 crore

Eli Lilly to pump $1 billion into India to boost contract manufacturing

The US pharma major to set up a manufacturing and supply hub in Hyderabad as part of a $1 billion investment aimed at boosting contract production in India

Realty's next address: NCR's growth arteries pulse via SPR, Sohna

Part-I of this three-part series dives into Delhi-NCR's SPR, Sohna, Dwarka Expressway, and Jewar Airport leading the charge

Cough syrup deaths: NHRC sends notices to MP, Rajasthan, Uttar Pradesh

NHRC issues notices to MP, Rajasthan and UP, asks states to probe children's deaths from alleged use of contaminated cough syrups

University of Western Australia aims to open India campuses by Aug 2026

Starting with an initial cohort of around 100 to 150 students, Littlefair said that UWA would particularly focus on business and science, technology, engineering, and mathematics (STEM) courses

Jan Aushadhi retailers ask govt to review minimum distance policy

Retailers say proximity of new outlets is hurting sales and seek higher trade margins along with GST loss compensation under the Jan Aushadhi scheme

Festival frenzy: Housing market sees room for growth after 3-quarter lull

Developers roll out slew of freebies, incentives to potential buyers

Health Secy reviews GMP norms with states after cough syrup deaths

Union Health Secretary Punya Salila Srivastava chaired a meeting with states after 11 children died in MP and Rajasthan, stressing strict GMP compliance and rational use of cough syrups in children

Centre revises rate structure for nearly 2,000 medical procedures

CGHS hospitals must accept new rates by Oct 13

MP children deaths: Contaminant found in cough syrup made by TN firm

Contaminant found in Coldrif cough syrup; risk-based investigations started at manufacturing sites of around 19 drugs sampled across 6 states

After 7 years, IHH finally gets Sebi go-ahead for Fortis open offer

In 2018, price was set at ₹170/share; Fortis Healthcare now trades at ₹980.10